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Dependence
Michael B. Knable, D.O.
The rapid escalation of cocaine abuse in the United States in the 1980 's has
generated a host of inte rest ing hypotheses on various aspect s of th is problem.
After a succinct discussion of epidemiologic, clinical , and neuro-pharmacologic
aspects of cocaine abuse, a survey of the current literature on psych ophar maco-
logic management of dependence is offere d . While several agents ha ve emerged
as usefu l adj unc tive treatments for abstinence syndromes it is important for the
cli nic ian to remember that th ere is not official approval for such treatments.
Additionally, psyc hotherapeutic maneuvers, which remain th e major tools in
treatment ofaddicts, should not be overlooked when an experimental pharmaco-
logic intervention is selected.
INTRODUCTION
In the last decade a dramat ic change in the social patterns of cocaine use has
forced th e med ica l co mm unity to witness th e devastation of a new epidemic. A
"cocaine epidemic" that seems so radically different from the fash iona b le
prevalence of cocaine use in the early par t of th is century has filled medical,
pediatric, psyc h iatric an d neonatal facilities and strained the limits of human and
material resources.
O ne is encouraged, however , by the new public awareness of the probl em.
T he federal government has begun to address the need for treatment more
d irectly. Knowledge of the medical consequences of cocaine use is more wide-
spread, due in par t to the vicissitudes of entertainers and ath letes who use
cocaine. T he DSM-IlIR has recognized diagnostic categories o f cocaine depen-
dence and withdrawal that draw upon recent stud ies of cocaine users.
An ad d it ional encouragement lies in the clear description of ab st inence
sym ptomatology. From an understand ing of phenomenology eme rges an at-
tempt to alleviate symptoms th rough the use of medications. Medication may be
a tool to help addicts to lerate withdrawal and then bec om e engaged in the
long-term psychosocial interventions that will probably be necessary for contin-
ued abstinence and improved functioning. This paper, after brie f co nsideration
of background ideas in epidemiology, clinical descriptions and phar maco logy,
will review medical treatments of withdrawal and dependence.
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Recent epidemiologic studies of cocaine use have been reviewed in detail
elsewhere (1-4), but a brief mention of important sta tist ics is in order.
A 1985 National Institute of Drug Abuse , Household Survey estimated that
3 million Americans are dependent on cocaine. About 25 mill ion Americans,
including 40% of the population between ages 25 and 30, have tried cocaine.
About 5.8% of high school seniors are current users.
Admissions to publicly-funded treatment centers, emergency room visits
that are cocaine related, and the number of cocaine related deaths increased
approximately 15 fold between 1976 and 1986.
CLINICAL MANIFESTATIONS
Descriptions of the effects of cocaine on the cardiovascul ar and nervous
systems are widely available. However, understanding of cocaine's psychiatric
effects has evolved in recent year s. After brief mention of the in te raction of
cocaine with mood and thought processes, new ideas about abstinence symptoms
will be presented.
Cocaine is classically described as a powerful euphoric. Use of cocaine as an
antidepressant though, has not gained favor. Despite Freud's conviction (5) that
cocaine was an effective therapy for depression , th is has not been corroborated
exper imenta lly in 10 depressed patients at the National Inst itute of Mental
Health (6). Furthermore, Post noticed that coca ine is not on ly ineffec tive as a
treatment for depression but may also be capable of inducin g dysphor ia (7). He
noticed that dysphoria associated with stimulant intoxicati on is simi lar clinically
to the depressed affect that often accompanies fulm inant man ia , and that
cocaine may potentiate sad affect in depressed patients. T he t ime course of these
events is unclear and Post may have been describing what are now understo od to
be withdrawal phenomena.
Psychosis is a seve re psychic manifestation of cocaine use. T he seminal work
o f Post (7) postulates a continuum of stimulant induced affect ive an d psychotic
sta tes with th e involvement of multiple neurochemical aberrat ions. Post has also
reviewed the literature regarding stimulants as determinan ts of pathological
behavio r and seizures through a mechanism similar to electr ica l kindling (8) .
The assertion that stim u lants may disrupt limbic func tion when used chroni-
call y, and through a kindling-like phenomenon, produce ch ronic affective and
sch izop hren ifor m syndromes, is a powerful idea. Preliminary evidence suggests
that long term st im ula n t abuse may cause degeneration of dopam inerg ic neu-
rons and lea ve the patient with an irreversibl e deficit in mood regu lation (1) .
Gawin and others (1 ,9) have produced a detailed descri ption of symptom-
atology when 30 coc a ine abusers were observed in abstinence . T hey divide
abst inence into " crash, " "withdrawal ," and "extinc tion" phases.
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The crash phase follows a binge . Acute dysphoria , anxiety and craving are
rep laced within a few hours by hypersomnolence and hype rp hagia . It is diffi cul t
to d istinguish crash sym ptoms fr om major depression , but one may suspect a
prima ry psychiatric d isorder if neurovegetative sym ptoms persist after slee p has
returned to normal and prolonged abs t ine nce ha s bee n ac hieved. The craving to
a llev iate crash effects is di scontinuous, unlike the craving seen with alc ohol an d
opiate withdrawal.
Withdrawal sym ptoms include a ner gia, a nhedonia, lack of interest an d
variab le levels of craving. T hese symptoms seem to peak at 12-96 hou rs.
Symptoms then remain in a fluctuating pattern and are generally not severe
enough to be confused with major depression. Lethargy and dysphoria usually
improve by 4-5 months of abstinence .
Extinction refers to th e brief, ep isod ic return of craving fo r cocai ne brought
about by the influence of conditioned cues. Many stim u li, such as objects or
circu ms tances formerly associated with drug use, and fantas ies or dreams of
drug use may spark craving. Su ch craving may return for man y months or even
yea rs. Ext inction is the removal of these conditioned cues.
Criticism of Gawin's model focuses on its naturali sti c design and its neglect
for recent reports of physical concomitants of a cocaine withdrawal syndrome ,
(m uscle pains, chills, tremor) (10) . T h is is an elegant framework for further
elucid ation of withdrawal phenomena, however.
CO-MORBIDITY
The relationship between psychopathology and d rug abuse is controversial.
Psychodynamic formulation s of subs ta nce abuse pathology have been well
sum mar ized by Wurmser (11). In hi s view, addict s exh ibi t rudi mentary ca paci ty
fo r use o f symbol and fantasy, inability to defend aga inst strong affects, a chronic
sea rc h ing to replace inadequate objects , self destruct iveness and regressive
gratification of narcissistic needs. Life 's difficulties co ntinua lly present a series of
narcissistic injuries to addicts which are defended agains t by drug use .
Only two studies have evaluated cocaine abusers fo r DSM-III , Axi s 1
co-mo rbid ity and these are sum mar ized by Gawin and Kleber (9) . Affective
di sorders, including major depression, dysthymia and atyp ical depressions are
found in 30 % of users, with minor depressions comprising the maj ority of this
group. Twenty percent of users are bipolar or cyclothymi c, and approximately
5% may be seen as having residual attention deficit di sorder.
Interestingly, 64% of cocaine users with DSM-III affec tive d iagn oses prefer
the intranasal route and have shorter "runs," su ggesting a cessation of drug use
wh en dysphoria is ameliorated (9).
Khantzian has been a major proponent for th e concept of drug abuse as se lf
medication for psychiatric di sorders (12). While Post 's NIM H study failed to
show eup hor ic response to cocaine in subj ects with maj or depression , Khantzian
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feels that patients with dysthymia or atyp ical depression may indeed respond to
stimulants and hence the basis for h is " self medication" hypo thesis. Khantzian
also believes cyclothymic patients sel f-medica te in order to reverse dysthymia
and maintain stab le hypomania. He also proposes that patien ts with attention
deficits may be able to improve their function with cocaine (9) . Flemenbaum (13 )
also was one of the first to see substance abuse as a parapsychiatri c symptom in
patients with affective disorders .
Studies of self-administration of cocaine in animals a nd humans suggest that
the incredibly pleasurable "reward" provided by cocaine may produce addictive
behavior in individuals not particularly predisposed by a psychi atr ic diagnosis.
Fischman (14,15) has shown that humans will self administe r IV solutions of
cocaine in a manner similar to animal models and has docu mented acute
tol erance to the cardiovascular and subj ective euphoric effec ts of cocaine . These
data suggest that coca ine is indeed a powerfully addictive substance and that
psychopathology is not necessarily a precursor of addiction.
ABUSE OF OTHER DRUGS
A problem which confounds treatment of coc aine users as much as psychiat-
ric co-morbidity is the presence of multiple subs ta nces of abuse. Kleber (16)
reports that 50% of cocaine users also abuse alcohol , 30 % use marihuana , 8% use
amphetamines, 5% use tranquilizers and 4 % use opiates. Experie nce in inner cit y
settings leads one to believe that polydrug abuse is the norm. A we ll known
phenomenon amongst heavy cocaine users is the development of a ne ed to
" t itra te" cocaine binges with depressant drugs. Man y users tu rn to alcohol ,
tranquilizers or narcotics to enabable sleep after chronic cocaine ingest ion.
Use of marijuana almost inevitably precedes cocaine use (4) . Ninety-Six
percent of cocaine users are former or concurrent users of marijuana and the
likelihood of cocaine use increases with the lifetime frequency of marijua na use .
PHARMACOLOGY
Many of the current physiologic concepts concerning neuroadaptat ion to
chronic cocaine abuse and the production of an abs tinence syndrome have their
basis in early models of intracranial self-stimulation. It has been known for
nearly thirty five years that animals will self administer electr ica l stimuli to
"pleasure centers" of the brain (17). The electrical stim uli are hypothesized to
activate certain neurotransmitter mediated " reward pathways." It has also been
found that animals will self administer central nervous syste m st imulants, espe-
cia lly when they are applied directly to reward pathways. Humans also self
administer cocaine in laboratory stud ies (18). Stimulant sel f ad ministration is
probably mediated largely by mesocortical and mesolimbic dopaminergic proj ec-
tions.
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Controversy arises when one tries to determine exac tly which transmitters
or which element of transmitter chemistry is affected by chronic stimulant abuse
and is therefore responsible for the neuroadaptation of add ict ion . Cocaine and
other stimulants cause neuronal release of norepinephrine , dopamine , and
possibly acetylcholine and serotonin. The re-uptake of th ese am ines is also
blocked by cocaine. Supersensitivity of ,B-adrenergic, a-adren ergic and dopami-
nergic receptors occurs with prolonged cocaine ad m in istra t ion . Bet a-receptor
supersensitivity is thought to contribute to depressive affect sta tes, and th is may
account for post-cocaine dysphoria.
The most compelling neurochemical explanations fo r cocaine ind uced
euphoria and post-cocaine dysphoria implicate dopamine. A recent study pro-
poses that dopamine re-uptake inhibition is the principal determinant of depen-
dence (19). Lesions produced in tegmental dopaminergic a reas wit h 6-
hydroxydopamine decrease self administration of cocaine (20). Pimozide (a
dopamine receptor blocker), but not phentolamine or phenoxybenzamine (nor-
adrenergic blockers), blocks self administration of cocain e (21 ). T he ability of
rats to discriminate for cocaine is attenuated by pimozide, haloperidol and
chlorpromazine, but this effect is not observed with propranolol , ph enoxyben-
zamine, a -methyl-para-tyrosine, or physostigmine (22) . It is also well kn own that
neuroleptics block amphetamine induced psychotic symptomatology in human s
(23). Reports that cocaine users develop hyperprolactinemia ma y indicate a
chronic depletion of dopamine (24). Some chronic cocaine users ha ve also been
observed to develop "pseudoparkinsonism" (25). Preliminary PET scan data
from cocaine addicts demonstrate disordered DOPA utilization in th e striatum
when 18-Auoro-DOPA is used as a tracer (26). Though this evidence seems to
favor an hypothesis of dopamine hypofunction or depletion , it must be remem-
bered that the evidence is not conclusive, and one must not be tempted to readi ly
accept the "one transmitter-one disease" model (27).
Cocaine's addictive potential also depends on the pharmacologic properties
of the different forms of abused cocaine. Intranasal , freebased and intravenous
cocaine are the patterns of use most commonly encountered, and th ere are
significant pharmacologic differences between them (28).
Intranasal cocaine HCI requires 3-5 minutes for onset of action and ha s a
mean half life of about one hour. Users commonly repeat the dose every 15- 20
minutes to maintain a high.
Intravenous cocaine HCI produces a " r ush" in 30-45 seconds and has a half
life of 10-20 minutes. The quick onset of action and shorter half life increase th e
addictive potential. Since the user must administer doses more frequent ly, in
ever increasing amounts, tolerance is achieved more rapidly than with intranasal
use.
Freebase cocaine is a basic salt of cocaine. Basic forms of cocaine are
preferred for cocaine smoking because they have a lower tempera tu re of
volatilization and are more lipid soluble than the HCI salt. " Crack" is a form of
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cocaine base which has been extracted with sodium bicarbonate. When basic
cocaine is smoke d it is absor bed very effic iently by the pulmonary vasc ulatu re. A
rush is obta ined in 8- 10 seco nds and the high remains for only 5-10 m inutes.
Hence , crack's rep utation as the most add ict ive form of cocaine .
PHARM ACOTHERAPI ES OF COCAI NE DEP EN DENCE
T he ul t imate goal of pha r macol ogic treatme nts is to obtain long te rm
abs tinence. Abstinence in itself may be a measurable effect from pharmacologic
tr eatm e nts. H owever, medications may also block the acute euphoric effects of
cocaine, and may be effective remed ies for wit hdrawal symptomatology. Blocked
euphoria and improved withdrawal symptoms are variables that medicati ons
may affec t and thereby fac ilitate abs tinence. Several different agents have been
stud ied for th ese effects.
ANTIDEPRESSANTS
Because chronic cocaine abuse has bee n associated with increased f3-
adrenergic, a-adrenergic an d dopam inergic receptor sensiti vity, antidepressants
have been suggested as a therapy for cocaine withdrawal. The rational e fo r thi s
choice lies in the abi lity of antidepressants to induce f3-adrenergic receptor
subsensitivity after a period of time corresponding to clinical improvement of
depressed affect. A nti depressants have been evaluated as agents for : blockade of
acute , cocaine induced eup hor ia, for reduc tion of withdrawal associated a nhe-
donia , dysphoria and craving, and fo r e ffec tors of prolonged abstinence .
Tennant and Rawson (29) reported an open tria l oflow dose desipramine in
14 cocaine a nd 8 a mpheta mine abusers. T hey fel t that cocaine abstinence was
im proved (5 pat ien ts relapsed within 45 days of admission) and that dysphoria ,
craving, and sleep disturbance were reduced. Three of22 subject s reported th at
desipramine blocked the effects of cocaine or amphetamine . They ba sed th eir
selection ofdesipramine on its ability to increase synaptic norepinephrine , whi ch
may be depl eted in chronic cocaine use , and not the drug's ability to decrease f3
recepto r sensitivity . H ence their tria l lasted on ly seven days.
Rosecan (30) reported substantia l reduction in cocaine use in 80% of
subjects wit h therapeut ic doses of imipramine (100-300 mgs./da y). Ro secan
a lso adminis te red 1000 mg. of tyrosine in the morning and 1000 mg . of
tryptophan at bedtime , a nd anecdotally observed that acute euphoria was
b locked an d that wit hdrawal associated craving was diminished.
Gawin and Kleber (3 1) conducted an open trial of desipramine in th erape u-
t ic doses (200 mg./day) in six users who had failed to stop cocaine use with
psycho therapy alone. All subjects eventually became abstinent and quantita tive
measures of craving were reduced by the third week of treatment. Decreased
craving occurred in subjects regardless of coexisting psychiatric diagnosis.
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These authors report a second trial of26 patients without a ffect ive d isorder
who had fai led to become abstinent after four weeks of psychotherapy and were
treated with desipramine, lithium, methylphenidate or psychotherapy (32).
Eighty percent of subjects with depressive symptoms who were treated with
desipramine were abstinent for four weeks after nine weeks of drug treatment.
Psychotherapy produced abstinence in 35 %. No lithium responders were noted
and methylphenidate was discontinued because patients tended to ex h ib it in-
creased craving after 2 weeks of treatment.
Rowbotham et al (33) performed a well controlled study evalua t ing the
possibility that serotonergic re-uptake blockade by an antidepressant may block
acute euphoria with cocaine. They also postulated that antidepressants affecting
serotonergic uptake ma y be safer in cocaine abusers since norepineph r ine
reuptake blockade by antidepressants and cocaine together may be synergistic
and dangerous. When subjects were pretreated with 100 mg. of trazod one , a 2
mg./kg. dose of cocaine still produced euphoria although th e sympa thomimetic
effects of cocaine were diminished.
One case report exists of 200 mg./day of trazodone producing rapid
improvement in withdrawal symptoms and effecting abstinence of 11 months.
The authors suggest that trazodone's lack of anticholinergic effec ts th at could
potentiate the sympathomimetic effects of cocaine ma y make trazodone a more
acceptable treatment than standard tricyclic antidepressants (34 ).
Baxter (35) reported two cases in which dysphoria and hypersomnolence
after the abrupt cessation of cocaine use were improved within 1-2 days after
initiation of desipramine treatment.
Giannini et al divided 20 cocaine abusers into those treated wit h 150
mg./day of desipramine and those receiving 25 mg./day of diphenhydramine as
placebo. They used the Hamilton Depression Rating Scale and clinical indices to
assess symptomatology and found that the placebo group developed significant
depression between days 0 and 20 of abstinence. Desipramine significantly
reduced depression between days 20 and 40 (36).
Gawin (32) has reported an ongoing double blind study compar ing desi-
pramine, lithium and placebo in 75 cocaine abusers. Data ha ve been co llected on
24 patients and reveal significant decreases in cocaine use and in craving from
four weeks after initiation of desipramine treatment. Plasma levels were also
monitored weekly and seem to suggest that cocaine addicts ma y require higher
plasma levels than depressed subjects.
LITHIUM
Work in the 1970's demonstrated that the behavioral man ifestations of
amphetamines and cocaine could be attenuated in laboratory animals wit h
lithium treatment (37) .
Angrist and Gershon (36) selected 8 patients with diverse psychi atric prob-
lems from an inpatient unit, and after stabilization, assessed th e effec ts of 0.5
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mg./kg. of d-arnphetamine on subjects before and after treatment wit h lithium.
They felt the attenuation of behavioral amphetamine effect s was variable but
that the pressor response of amphetamine was attenuated uniformly.
Amphetamine abuse was spo nt aneously discontinued in 2 patients who
cou ld not experience euphoria from amphetamines while recei ving lithium (39).
Cronson and Flemenbaum reported 5 anecdotal cases in whi ch cocaine induced
euphoria was prevented by lithium treatment (40).
Scott and Mullaly reported on 2 heavy cocaine users wh o had developed
chronic refractory psychoses and were successfully treated with lith ium (4 1). A
third patient with psychotic depression also improved and denied euphoric
effects of cocaine while taking lithium.
Gawin and Kleber , in their open trial, found four of five cycloth ym ic
patients treated with lithium to be abstinent at three months (3 1). Patients wit h
DSM-I II diagnoses of depression or dysthymia did not improve with lithium, an d
lithium did not appear to b lock cocaine induced euphoria.
Gawin and Kleber (32) in their ongoing double blind study have found th at
lithium reduces craving rapidly and for about one week. Craving and use of
cocaine appeared to increase to baseline levels after this period.
BROMOCRIPTINE, AMANTADINE, L-DOPA
Because cocaine acutely increases synaptic release of dopamine , blocks the
re-uptake of dopamine, and may chronically lead to a dopamine depletion sta te,
drugs affecting dopaminergic systems have begun to be studied. Bromocriptine
is an ergot derivative that has agonistic effects at dopamine receptors in various
brain sites. Amantadine releases dopamine and norepinephrine from neuronal
storage sites and slows re-uptake of dopamine and norepinephrine.
A small double blind study comparing placebo to a single dose ofbromocrip-
tine (0.625 mg.) in two cocaine abusers with dysphoria and intense craving
resulted in marked improvement in self rating of craving with bromoc r ip tine in
six repeated trials (42) .
An anecdotal report on 7 users with DSM-III diagnoses of cocaine abuse
and attention deficit disorder (ADD) found global improvement of atten tion and
craving when bromocriptine was begun at 0.625 mg. t.i.d., and increased to a
range of 7.5-12 .5 mg./day. These patients were abstinent during foll ow-up
periods ranging from 3 to 9 months (43) .
Tennant and Sagherian (44) performed a double blind study of 14 use rs
comparing bromocriptine (5.0-7.5 mg./day) with amantadine (100- 300 mg./
day). Only one subject treated with bromocriptine was able to complete ten days
of treatment due to side effects. The subjective improvements in crav ing an d
dysphoria were similar for bromocriptine and amantadine. However, th e " mean
daily withdrawal score" indicated better performance with amantadine. T hese
patients also received daily doses of tyrosine and tryptophan , and though this
would not confound differences between bromocriptine and amantadine , th ese
PHARMACOLOGIC TREATMENTS OF COCAINE DEPENDENCE II
amino acids may provide some palliative effect in themselves. Bromocr iptine was
also reported to block cocaine induced euphoria, and the authors postulate that
bromocriptine may be well suited to treatment of patients who require partial
agonist/antagonist therapy similar to naltrexone. They also felt that amanta-
dine was safer and more effective in an ambulatory setting.
Giannini et al (45) performed a double-blind study for six wee ks compari ng
bromocriptine to placebo in 24 cocaine addicts. Patients receivin g bromocr ip-
tine (0.625 mg q.i.d .) had significant improvements on th e Br ie f Psychiatric
Rating Scale when compared to placebo. The authors conclude th at brornocr ip-
tine is an effective and fast acting treatment for withdrawal.
An open trial of 10 mg. carbidopa and 100 mg. L-d opa (b .i.d. or t .i.d .) for
1-2 weeks in "several" cocaine abusers resulted in "some response" in an
attempt to alleviate withdrawal symptoms (46) .
STIMULANTS
Stimulants such as methylphenidate are pharmacologicall y similar to co-
caine and share cross tolerance with cocaine. Khantzian (47) descr ibed a heavy
cocaine user successfully treated with methylphenidate 15 mg. t .i.d . and postu-
lated a residual ADD leading to self medication with coca ine .
A second report (48) of three patients also meeting some criteria for ADD
further supported the self medication hypothesis . Patients sh owed improvement
in withdrawal symptoms.
Methylphenidate was not effective in producing cocaine abstinence in five
abusers without ADD symptomatology despite 2-5 week trials in dosages up to
100 mg. daily (49).
Magnesium pemoline in doses of 75-225 mg./day was reported to be
effective in 2 patients with presumed residual ADD. These patients experien ced
improvements in withdrawal symptoms and in long term ab stinence (50).
Gawin (32) has reported that methylphenidate actually increases cocaine
craving after a 1-2 week period of treatment in patients without ADD and
proposes that a mi ld euphoria associated with methylphenidate use acts as a
conditioned cue to resume cocaine use. The possibility of toxic interactions
between stimulants and cocaine has not been evaluated full y and th is must be
kept in mind, especially in patients likely to abuse stimu lants as well as cocaine.
TYROSINE
Based on the hypothesis that cocaine depletes catecholamines and tha t
tyrosine may increase the synthesis of dopamine, norepinephrine and epineph-
rine, Gold et al (5 1) administered 0.1 mg/kg. of tyrosine to 6 add icts undergoing
withdrawal. Tyrosine had "consistent anti-withdrawal effect s" in an unspecified
period of time. These data are interesting and merit further investigation since
the relative innocuousness and low abuse potential of tyrosine are attractive.
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T h ree antidepressants, desipramine, imipramine and trazodone , ha ve bee n
stu d ied for their effects on cocaine addicts.
Desip ramine is mentioned as an age n t capable of p roducing abstinence in 3
uncontrolled and 1 controlled study. The length of abst inence varies from one
to many months.
Desipramine improved withdrawal symptomatology, including dysphoria
and craving, in 2 controlled and 3 uncontrolled studies. Desip ramine seemed to
help immediately in 2 studies, but required 2-4 weeks for effectiveness in th e
remainder.
One uncontrolled study states that desipramine block s acute euphoria
associated with cocaine ingestion .
Imipramine, in one uncon tro lled study, was found to be an effec tive agent
for abstinence, withdrawal symptomatology and inhibition of acute euphoria .
Trazodone was found to be effective in the treatment of withdrawal symp-
toms and in maintaining abstinence in one uncontrolled paper. One controlled
study found that trazodone did not block acute euphoria.
Lithium was found to be an effecto r of abstinence when restricted to
cyclo thy mic patients in one uncontrolled study. In one co ntrolled study lithium
was felt to have a transient effec t on abstinence.
One controlled study found lithium to have a brie f, palli ative effect on
withdrawal symptoms (fo r about one week).
Three uncontrolled reports found that lithium is an inhibitor of cocaine
induced e uphor ia . One uncontrolled study found this e ffec t to be lacking .
One case report has found lithium to be an effec tive treatment for pro-
longed psychosis and/or psychotic depression foll owing heavy, chronic cocaine
use .
Bromocriptine, in three controlled studies and in o ne uncontrolled study,
see ms to alleviate dysphoria and craving. It seems to exe r t this effec t rapidl y but
is often associated with unpleasant side effects.
Bromocriptine is reported to have helped achieve abstinence in one uncon-
trolled and in one controlled study.
In one uncontrolled report bromocriptine was fe lt to block cocai ne-ind uced
euphoria.
Amantadine was found to improve withdrawal symptoms in o ne contro lled
study.
L-dopa was found helpful in treating withdrawal sym pto ms in one case
report.
Stimulants have been reported as effective treatments for withdrawal in two
uncontrolled studies. However, one uncontrolled and one co ntrolled study
found that stimulants may worsen withdrawal sym ptoms.
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T wo uncontrolled reports cite sti mu lan ts as helpful in obtaining abstinence.
Man y of the stud ies in volvi ng st im u lants we re perfo r med on patients with
presumptive , premorbid di agn oses of attention deficit d isorde r.
CONCLUSION
This review has presented issues in epidem iologic, clinical and neurophar-
ma cologic aspect s of cocaine abuse. Further research into these areas can be
expected to highlight severa l questi ons. Further eluc idation of a cocaine with-
drawal syndrome in large cohor ts, utilizing fu ll descriptive and physiolog ic
measures may more clearly define "subsy ndrornes" th at wou ld respond favor-
ab ly to tailored forms of therapy. Long te rm prospect ive studies evaluating th e
presence o f pre-existent psychiatric di agnoses are necessary. The att empt to
relate animal models to the neurophysiology of addicti ve behaviors in humans is
a very murky area which under-scores the traditional gulf between descriptive
and pathophysiologic knowledge in psychiatry. Anatomic evidence for dopa-
mine depletion in the brain is still lacking, but presu m ptive evidence would
suggest its presence in co caine abusers.
The psychopharmacologic management of cocaine depende nce is a young
and developing field. Current studies are quite prelimi nary; for the most part
an ecdotal and involve small numbers of patients. Since most reports are favor-
abl e , one is tempted to consider pharmacotherapy as an attractive adjunct to
psychotherapy. Perhaps, with the allev ia tion o f withd rawal symptoms, patients
ar e made more " availab le" for psychotherapeutic work.
From the work that is currently available it would see m th at lithium,
dopaminergic agonists, and, possibly, in a proportion of add icts wit h premorbid
attention deficits, stimulants, act rather quickl y to improve craving and dyspho-
ria during coca ine withd rawal. Perhaps these agents will be seen as especially
useful for the acute, inpatient management of withdrawal. O ne is also hopeful
that antidepressant therapy may emerge as an especially useful tool for treating
the long term feelings of dysphoria and craving that so often preclude long term
abstinence.
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